Clinical implications of microRNAs in liver cancer stem cells

Chinese Journal of Cancer

Volumn 32, Issue 8, 2013, Pages 419-426

  Chai, Stella ^a   Ma, Stephanie ^a,b  

^a Department of Clinical Oncology ^*  (Hong Kong)

^b THE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Hepatocellular carcinoma; Liver cancer stem cells; Microrna

Indexed keywords

ADENOVIRUS VECTOR; ANTISENSE OLIGONUCLEOTIDE; DOXORUBICIN; LET 7; LIPOSOME; MICRORNA; MICRORNA 122; MICRORNA 124; MICRORNA 130B; MICRORNA 145; MICRORNA 150; MICRORNA 181; MICRORNA 199 A 3P; MICRORNA 21; MICRORNA 26A; SORAFENIB; UNCLASSIFIED DRUG;

ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER STEM CELL; CANCER TISSUE; CARCINOMA IN SITU; CLINICAL FEATURE; GENE EXPRESSION; HUMAN; LIVER CANCER; LIVER CELL CARCINOMA; NONHUMAN; RECURRENCE RISK;

CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER; LIVER NEOPLASMS; MICRORNAS; NEOPLASTIC STEM CELLS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84881271975     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.013.10038     Document Type: Article

References (108)

1. Cancer facts and figures 2012. American Cancer Society. 2012. Accessed at http://www.cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2012.
2. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 2010,127:2893- 2917.
3. Aravalli RN, Steer CJ, Cressman EN. Molecular mechanisms of hepatocellular carcinoma. Hepatology, 2008,48:2047-2063.
4. Qi J, Wang J, Katayama H, et al. Circulating microRNAs (cmiRNAs) as novel potential biomarkers for hepatocellular carcinoma. Neoplasma, 2013,60:135-142.
5. Tong CM, Ma S, Guan XY. Biology of hepatic cancer stem cells. J Gastroenterol Hepatol, 2011,26:1229-1237.
6. Clevers H. The cancer stem cell: premises, promises and challenges. Nat Med, 2011,17:313-319.
7. Nagano H, Ishii H, Marubashi S, et al. Novel therapeutic target for cancer stem cells in hepatocellular carcinoma. J Hepatobiliary Pancreat Sci, 2012,19:600-605.
8. Chiba T, Kita K, Zheng YW, et al. Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology, 2006,44:240-251.
9. Ma S, Chan KW, Hu L, et al. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology, 2007,132:2542-2556.
10. + HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene, 2008,27:1749-1758.
11. Fan L, He F, Liu H, et al. CD133: a potential indicator for differentiation and prognosis of human cholangiocarcinoma. BMC Cancer, 2011,11:320.
12. + cancer stem cells in human liver cancer. Cancer Cell, 2008,13:153-166.
13. Endo K, Terada T. Protein expression of CD44 (standard and variant isoforms) in hepatocellular carcinoma: relationships with tumor grade, clinicopathologic parameters, p53 expression, and patient survival. J Hepatol, 2000,32:78-84.
14. + cell population in hepatocellular carcinoma cell lines. Cancer Sci, 2010,101:2145- 2155.
15. Lee TK, Castilho A, Cheung VC, et al. CD24(+) liver tumor-initiating cells drive self-renewal and tumor initiation through STAT3- mediated NANOG regulation. Cell Stem Cell, 2011,9:50-63.
16. Yoon SK. The biology of cancer stem cells and its clinical implication in hepatocellular carcinoma. Gut Liver, 2012,6:29-40.
17. Reinhart BJ, Slack FJ, Basson M, et al. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature, 2000,403:901-906.
18. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell, 1993,75:843-854.
19. Kasinski AL, Slack FJ. Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer, 2011,11:849-864.
20. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer, 2006,6:857-866.
21. Borel F, Konstantinova P, Jansen PL. Diagnostic and therapeutic potential of miRNA signatures in patients with hepatocellular carcinoma. J Hepatol, 2012,56:1371-1383.
22. Etheridge A, Lee I, Hood L, et al. Extracellular microRNA: a new source of biomarkers. Mutat Res, 2011,717:85-90.
23. Meng F, Glaser SS, Francis H, et al. Functional analysis of microRNAs in human hepatocellular cancer stem cells. J Cell Mol Med, 2012,16:160-173.
24. Zhao X, Yang Z, Li G, et al. The role and clinical implications of microRNAs in hepatocellular carcinoma. Sci China Life Sci, 2012,55:906-919.
25. Ji J, Yamashita T, Budhu A, et al. Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells. Hepatology, 2009,50:472-480.
26. Ji J, Yamashita T, Wang XW. Wnt/beta-catenin signaling activates microRNA-181 expression in hepatocellular carcinoma. Cell Biosci, 2011,1:4.
27. Xu J, Wu C, Che X, et al. Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol Carcinog, 2011,50:136-142.
28. Li LM, Hu ZB, Zhou ZX, et al. Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma. Cancer Res, 2010,70:9798-9807.
29. Ma S, Tang KH, Chan YP, et al. miR-130b promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1. Cell Stem Cell, 2010,7:694-707.
30. Liu AM, Yao TJ, Wang W, et al. Circulating miR-15b and miR- 130b in serum as potential markers for detecting hepatocellular carcinoma: a retrospective cohort study. BMJ Open, 2012, 2:e000825.
31. Zhang J, Luo N, Luo Y, et al. microRNA-150 inhibits human CD133- positive liver cancer stem cells through negative regulation of the transcription factor c-Myb. Int J Oncol, 2012,40:747-756.
32. Jia Y, Liu H, Zhuang Q, et al. Tumorigenicity of cancer stem-like cells derived from hepatocarcinoma is regulated by microRNA-145. Oncol Rep, 2012,27:1865-1872.
33. Henry JC, Park JK, Jiang J, et al. miR-199a-3p targets CD44 and reduces proliferation of CD44 positive hepatocellular carcinoma cell lines. Biochem Biophys Res Commun, 2010,403:120-125.
34. Sassen S, Miska EA, Caldas C. MicroRNA: implications for cancer. Virchows Arch, 2008,452:1-10.
35. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A, 2008,105:10513-10518.
36. Hsu SH, Wang B, Kota J, et al. Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J Clin Invest, 2012,122:2871-2883.
37. Kota J, Chivukula RR, O'Donnell KA, et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell, 2009,137:1005-1017.
38. Hatziapostolou M, Polytarchou C, Aggelidou E, et al. An HNF4α-miRNA inflammatory feedback circuit regulates hepatocellular oncogenesis. Cell, 2011,147:1233-1247.
39. Callegari E, Elamin BK, Giannone F, et al. Liver tumorigenicity promoted by microRNA-221 in a mouse transgenic model. Hepatology, 2012,56:1025-1033.
40. Park JK, Kogure T, Nuovo GJ, et al. miR-221 silencing blocks hepatocellular carcinoma and promotes survival. Cancer Res, 2011,71:7608-7616.
41. Qu KZ, Zhang K, Li H, et al. Circulating microRNAs as biomarkers for hepatocellular carcinoma. J Clin Gastroenterol, 2011,45:355- 360.
42. Zheng J, Dong P, Gao S, et al. High expression of serum miR-17- 5p associated with poor prognosis in patients with hepatocellular carcinoma. Hepatogastroenterology, 2012,in press.
43. Chen L, Jiang M, Yuan W, et al. miR-17-5p as a novel prognostic marker for hepatocellular carcinoma. J Invest Surg, 2012,25:156- 161.
44. Li L, Guo Z, Wang J, et al. Serum miR-18a: a potential marker for hepatitis B virus-related hepatocellular carcinoma screening. Dig Dis Sci, 2012,57:2910-2916.
45. Tomimaru Y, Eguchi H, Nagano H, et al. Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma. J Hepatol, 2012,56:167-175.
46. Li J, Wang Y, Yu W, et al. Expression of serum miR-221 in human hepatocellular carcinoma and its prognostic significance. Biochem Biophys Res Commun, 2011,406:70-73.
47. Qi P, Cheng SQ, Wang H, et al. Serum microRNAs as biomarkers for hepatocellular carcinoma in Chinese patients with chronic hepatitis B virus infection. PLoS One, 2011,6:e28486.
48. Gui J, Tian Y, Wen X, et al. Serum microRNA characterization identifies miR-885-5p as a potential marker for detecting liver pathologies. Clin Sci (Lond), 2011,120:183-193.
49. Liu WH, Yeh SH, Lu CC, et al. MicroRNA-18a prevents estrogen receptor-alpha expression, promoting proliferation of hepatocellular carcinoma cells. Gastroenterology, 2009,136:683-693.
50. Han ZB, Zhong L, Teng MJ, et al. Identification of recurrence-related microRNAs in hepatocellular carcinoma following liver transplantation. Mol Oncol, 2012,6:445-457.
51. Karakatsanis A, Papaconstantinou I, Gazouli M, et al. Expression of microRNAs, miR-21, miR-31, miR-122, miR-145, miR-146a, miR-200c, miR-221, miR-222, and miR-223 in patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma and its prognostic significance. Mol Carcinog, 2013,52:297-303.
52. Meng F, Henson R, Wehbe-Janek H, et al. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology, 2007,133:647-658.
53. Zhu Q, Wang Z, Hu Y, et al. miR-21 promotes migration and invasion by the miR-21-PDCD4-AP-1 feedback loop in human hepatocellular carcinoma. Oncol Rep, 2012,27:1660-1668.
54. Zhang J, Yang Y, Yang T, et al. microRNA-22, downregulated in hepatocellular carcinoma and correlated with prognosis, suppresses cell proliferation and tumourigenicity. Br J Cancer, 2010,103:1215-1220.
55. Wang B, Hsu SH, Frankel W, et al. Stat3-mediated activation of microRNA-23a suppresses gluconeogenesis in hepatocellular carcinoma by down-regulating glucose-6-phosphatase and peroxisome proliferator-activated receptor gamma, coactivator 1 alpha. Hepatology, 2012,56:186-197.
56. Yang X, Liang L, Zhang XF, et al. MicroRNA-26a suppresses tumor growth and metastasis of human hepatocellular carcinoma by targeting IL-6-Stat3 pathway. Hepatology, 2013,in press.
57. Xiong Y, Fang JH, Yun JP, et al. Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma. Hepatology, 2010,51:836-845.
58. Wang CM, Wang Y, Fan CG, et al. miR-29c targets TNFAIP3, inhibits cell proliferation and induces apoptosis in hepatitis B virus-related hepatocellular carcinoma. Biochem Biophys Res Commun, 2011,411:586-592.
59. Yao J, Liang L, Huang S, et al. MicroRNA-30d promotes tumor invasion and metastasis by targeting Galphai2 in hepatocellular carcinoma. Hepatology, 2010,51:846-856.
60. Li N, Fu H, Tie Y, et al. miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells. Cancer Lett, 2009,275:44-53.
61. Li D, Liu X, Lin L, et al. MicroRNA-99a inhibits hepatocellular carcinoma growth and correlates with prognosis of patients with hepatocellular carcinoma. J Biol Chem, 2011,286:36677-36685.
62. Petrelli A, Perra A, Schernhuber K, et al. Sequential analysis of multistage hepatocarcinogenesis reveals that miR-100 and PLK1 dysregulation is an early event maintained along tumor progression. Oncogene, 2012,31:4517-4526.
63. Zhang Y, Guo X, Xiong L, et al. MicroRNA-101 suppresses SOX9- dependent tumorigenicity and promotes favorable prognosis of human hepatocellular carcinoma. FEBS Lett, 2012,586:4362-4370.
64. Su H, Yang JR, Xu T, et al. MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer Res, 2009,69:1135-1142.
65. Shen G, Jia H, Tai Q, et al. miR-106b downregulates adenomatous polyposis coli and promotes cell proliferation in human hepato-cellular carcinoma. Carcinogenesis, 2013,34:211-219.
66. Zheng F, Liao YJ, Cai MY, et al. The putative tumour suppressor mi croRNA-124 modul ates hepatocel l ul ar carci noma cel l aggressiveness by repressing ROCK2 and EZH2. Gut, 2012, 61:278-289.
67. Bi Q, Tang S, Xia L, et al. Ectopic expression of MiR-125a inhibits the proliferation and metastasis of hepatocellular carcinoma by targeting MMP11 and VEGF. PLoS One, 2012,7:e40169.
68. Kim JK, Noh JH, Jung KH, et al. Sirtuin7 oncogenic potential in human hepatocellular carcinoma and its regulation by the tumor suppressors MiR-125a-5p and MiR-125b. Hepatology, 2013,57:1055-1067.
69. Chen X, Zhang L, Zhang T, et al. Methylation-mediated repression of microRNA 129-2 enhances oncogenic SOX4 expression in HCC. Liver Int, 2013,33:476-486.
70. Wang W, Zhao LJ, Tan YX, et al. MiR-138 induces cell cycle arrest by targeting cyclin D3 in hepatocellular carcinoma. Carcinogenesis, 2012,33:1113-1120.
71. Wong CC, Wong CM, Tung EK, et al. The microRNA miR- 139 suppresses metastasis and progression of hepatocellular carcinoma by down-regulating Rho-kinase 2. Gastroenterology, 2011,140:322-331.
72. Yang H, Fang F, Chang R, et al. MicroRNA-140-5p suppresses tumor growth and metastasis by targeting TGFBR1 and FGF9 in hepatocellular carcinoma. Hepatology, 2013,in press.
73. Zhang X, Li u S, Hu T, et al. Up-regul ated mi croRNA-143 transcribed by nuclear factor kappa B enhances hepatocarcinoma metastasis by repressing fibronectin expression. Hepatology, 2009,50:490-499.
74. Law PT, Chi ng AK, Chan AW, et al. mi R-145 modul ates multiple components of the insulin-like growth factor pathway in hepatocellular carcinoma. Carcinogenesis, 2012,33:1134-1141.
75. Ding J, Huang S, Wu S, et al. Gain of miR-151 on chromosome 8q24.3 facilitates tumour cell migration and spreading through downregulating RhoGDIA. Nat Cell Biol, 2010,12:390-399.
76. Han ZB, Chen HY, Fan JW, et al. Up-regulation of microRNA-155 promotes cancer cell invasion and predicts poor survival of hepatocellular carcinoma following liver transplantation. J Cancer Res Clin Oncol, 2012,138:153-161.
77. Wang J, Li J, Shen J, et al. MicroRNA-182 downregulates metastasis suppressor 1 and contributes to metastasis of hepatocellular carcinoma. BMC Cancer, 2012,12:227.
78. Li J, Fu H, Xu C, et al. miR-183 inhibits TGF-beta1-induced apoptosis by downregulation of PDCD4 expression in human hepatocellular carcinoma cells. BMC Cancer, 2010,10:354.
79. He Y, Cui Y, Wang W, et al. Hypomethylation of the hsa-miR-191 locus causes high expression of hsa-miR-191 and promotes the epithelial-to-mesenchymal transition in hepatocellular carcinoma. Neoplasia, 2011,13:841-853.
80. Xu C, Liu S, Fu H, et al. MicroRNA-193b regulates proliferation, migration and invasion in human hepatocellular carcinoma cells. Eur J Cancer, 2010,46:2828-2836.
81. 1/S transition of human hepatocellular carcinoma cells. Hepatology, 2009,50:113-121.
82. Tan S, Li R, Ding K, et al. miR-198 inhibits migration and invasion of hepatocellular carcinoma cells by targeting the HGF/c-MET pathway. FEBS Lett, 2011,585:2229-2234.
83. Fornari F, Milazzo M, Chieco P, et al. miR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res, 2010,70:5184-5193.
84. Shen Q, Cicinnati VR, Zhang X, et al. Role of microRNA-199a- 5p and discoidin domain receptor 1 in human hepatocellular carcinoma invasion. Mol Cancer, 2010,9:227.
85. Ying Q, Liang L, Guo W, et al. Hypoxia-inducible microRNA-210 augments the metastatic potential of tumor cells by targeting vacuole membrane protein 1 in hepatocellular carcinoma. Hepatology, 2011,54:2064-2075.
86. Shih TC, Tien YJ, Wen CJ, et al. MicroRNA-214 downregulation contributes to tumor angiogenesis by inducing secretion of the hepatoma-derived growth factor in human hepatoma. J Hepatol, 2012,57:584-591.
87. Wang X, Chen J, Li F, et al. miR-214 inhibits cell growth in hepatocellular carcinoma through suppression of β-catenin. Biochem Biophys Res Commun, 2012,428:525-531.
88. Chen PJ, Yeh SH, Liu WH, et al. Androgen pathway stimulates microRNA-216a transcription to suppress the tumor suppressor in lung cancer-1 gene in early hepatocarcinogenesis. Hepatology, 2012,56:632-643.
89. Huang N, Lin J, Ruan J, et al. miR-219-5p inhibits hepatocellular carcinoma cell proliferation by targeting glypican-3. FEBS Lett, 2012,586:884-891.
90. Zhang Y, Takahashi S, Tasaka A, et al. Involvement of microRNA- 224 in cell proliferation, migration, invasion and anti-apoptosis in hepatocellular carcinoma. J Gastroenterol Hepatol, 2013,28:565- 575.
91. Zhou P, Jiang W, Wu L, et al. miR-301a is a candidate oncogene that targets the homeobox gene Gax in human hepatocellular carcinoma. Dig Dis Sci, 2012,57:1171-1180.
92. Dohi O, Yasui K, Gen Y, et al. Epigenetic silencing of miR-335 and its host gene MEST in hepatocellular carcinoma. Int J Oncol, 2013,42:411-418.
93. Huang XH, Wang Q, Chen JS, et al. Bead-based microarray analysis of microRNA expression in hepatocellular carcinoma: miR- 338 is downregulated. Hepatol Res, 2009,39:786-794.
94. Fu X, Tan D, Hou Z, et al. miR-338-3p is down-regulated by hepatitis B virus X and inhibits cell proliferation by targeting the 3'- UTR region of Cyclin D1. Int J Mol Sci, 2012,13:8514-8539.
95. Gu H, Guo X, Zou L, et al. Upregulation of microRNA-372 associates with tumor progression and prognosis in hepatocellular carcinoma. Mol Cell Biochem, 2013,375:23-30.
96. Wu N, Liu X, Xu X, et al. MicroRNA-373, a new regulator of protein phosphatase 6, functions as an oncogene in hepatocellular carcinoma. FEBS J, 2011,278:2044-2054.
97. He XX, Chang Y, Meng FY, et al. MicroRNA-375 targets AEG-1 in hepatocellular carcinoma and suppresses liver cancer cell growth in vitro and in vivo. Oncogene, 2012,31:3357-3369.
98. Weng Z, Wang D, Zhao W, et al. microRNA-450a targets DNA methyltransferase 3a in hepatocellular carcinoma. Exp Ther Med, 2011,2:951-955.
99. Zhang LY, Liu M, Li X, et al. miR-490-3p modulates cell growth and epithelial to mesenchymal transition of hepatocellular carcinoma cells by targeting endoplasmic reticulum-Golgi intermediate compartment protein 3 (ERGIC3). J Biol Chem, 2013,288:4035- 4047.
100. Fornari F, Milazzo M, Chieco P, et al. In hepatocellular carcinoma miR-519d is up-regulated by p53 and DNA hypomethylation and targets CDKN1A/p21, PTEN, AKT3 and TIMP2. J Pathol, 2012,227:275-285.
101. Zhang W, Kong G, Zhang J, et al. MicroRNA-520b inhibits growth of hepatoma cells by targeting MEKK2 and cyclin D1. PLoS One, 2012,7:e31450.
102. Zhang S, Shan C, Kong G, et al. MicroRNA-520e suppresses growth of hepatoma cells by targeting the NF-κB-inducing kinase (NIK). Oncogene, 2012,31:3607-3620.
103. Tian Q, Liang L, Ding J, et al. MicroRNA-550a acts as a pro-metastatic gene and directly targets cytoplasmic polyadenylation element-binding protein 4 in hepatocellular carcinoma. PLoS One, 2012,7:e48958.
104. Yang L, Ma Z, Wang D, et al. MicroRNA-602 regulating tumor suppressive gene RASSF1A is overexpressed in hepatitis B virus-infected liver and hepatocellular carcinoma. Cancer Biol Ther, 2010,9:803-808.
105. El Tayebi HM, Hosny KA, Esmat G, et al. miR-615-5p is restrictedly expressed in cirrhotic and cancerous liver tissues and its overexpression alleviates the tumorigenic effects in hepatocellular carcinoma. FEBS Lett, 2012,586:3309-3316.
106. Zhang JF, He ML, Fu WM, et al. Primate-specific microRNA-637 inhibits tumorigenesis in hepatocellular carcinoma by disrupting signal transducer and activator of transcription 3 signaling. Hepatology, 2011,54:2137-2148.
107. Zeng ZL, Li FJ, Gao F, et al. Upregulation of miR-650 is correlated with down-regulation of ING4 and progression of hepatocellular carcinoma. J Surg Oncol, 2013,107:105-110.
108. Zhang L, Yang L, Liu X, et al. MiR-657 promotes tumorigenesis in hepatocellular carcinoma by targeting transducin-like enhancer protein 1 through NF-κB pathways. Hepatology, 2013,57:1919- 1930.